Abstract | BACKGROUND AND AIMS: METHODS: Based on bioinformatics, public databases and our in-house RNA-Seq database, we analyzed the clinical value and molecular mechanism of PPP2CA in HCC. RESULTS: Data were analyzed from 2,545 patients with HCC and 1,993 controls without HCC indexed in The Cancer Genome Atlas database, the Gene Expression Omnibus database and our in-house RNA-Seq database. PPP2CA expression was significantly higher in HCC tissue than in non-cancerous tissues (standardized mean difference: 0.69, 95% confidence interval [CI]: 0.50-0.89). PPP2CA expression was able to differentiate HCC from non-HCC, with an area under the summary receiver operator characteristic curve of 0.79 (95% CI: 0.75-0.83). Immunohistochemistry of tissue sections confirmed that PPP2CA protein was up-regulated in HCC tissues. High PPP2CA expression in HCC patients was associated with shorter overall, progression-free and disease-free survival. Potential molecular pathways through which PPP2CA may be involved in HCC were determined using miRWalk 2.0 as well as analysis of Gene Ontology categories, Kyoto Encyclopedia of Genes and Genomes pathways, and protein-protein interaction networks. CONCLUSIONS: PPP2CA is up-regulated in HCC and higher expression correlates with worse prognosis. PPP2CA shows potential as a diagnostic marker for HCC. Future studies should examine whether PPP2CA contributes to HCC through the candidate microRNAs, pathways and hub genes identified in this study.
|
Authors | Cheng-Lei Yang, Xue Qiu, Jin-Yan Lin, Xiao-Yu Chen, Yu-Mei Zhang, Xiao-Yin Hu, Jian-Hong Zhong, Shen Tang, Xi-Yi Li, Bang-De Xiang, Zhi-Ming Zhang |
Journal | Journal of clinical and translational hepatology
(J Clin Transl Hepatol)
Vol. 9
Issue 5
Pg. 661-671
(Oct 28 2021)
ISSN: 2225-0719 [Print] United States |
PMID | 34722181
(Publication Type: Journal Article)
|
Copyright | © 2021 Authors. |